Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of L-Lysine Amino Acid-Based Co-Crystal of Telmisartan Using Crystal Engineering Approach to Improve Solubility, Dissolution, and Micrometric Properties

Author(s): Nitin Kumar Bhatt, Jamshed Haneef, Manish Vyas and Gopal L. Khatik*

Volume 18, Issue 5, 2021

Published on: 02 September, 2020

Page: [596 - 606] Pages: 11

DOI: 10.2174/1567201817666200902151528

Price: $65

Abstract

Aim: To develop a co-crytsal of Telmisartan for enhancing its solubility in water.

Background: Intermolecular interaction happens in crystal packing; it utilizes and helps to understand the design of new solid with their respective chemical and physical properties called crystal engineering. It is a blueprint of molecular solids with specific chemical and physical properties through an understanding and handling of intermolecular interaction for increasing the solubility, in case of poor water-soluble drugs.

Objectives: The study was taken under consideration with an aim to generate and synthesize a cocrystal form of Telmisartan (TEL) with L-lysine to improve its water solubility, dissolution, and micrometric properties.

Methods: Using dry grinding technique, solvent evaporation and cooling crystallization, the results revealed a generation of co-crystals with enhanced solubility by liquid drop grinding method. Hence, this process was further explored to investigate various formulations and process parameters that could significantly affect the crystal solubility, dissolution, and micrometric properties.

Results: The solubility of TEL co-crystals was enhanced by L-lysine. Further, the optimized batch was subjected to its micrometric evaluation and physiochemical characterization like FT-IR, NMR, PXRD. The result of the micrometric evaluation showed better results as compared to standards. The dissolution studies also showed a better dissolution rate for TEL co-crystal tablets than TEL tablets formulation.

Conclusion: Co-crystals of TEL with L-lysine showed better solubility and dissolution rate.

Keywords: Cocrystal, telmisartan, L-lysine, solubility, dissolution, conformer.

« Previous Next »
Graphical Abstract

[1]
Desiraju, G. Crystal engineering: A brief overview. J. Chem. Sci., 2010, 122(5), 667-675.
[http://dx.doi.org/10.1007/s12039-010-0055-2]
[2]
Miroshnyk, I.; Mirza, S.; Sandler, N. Pharmaceutical co-crystals-an opportunity for drug product enhancement. Expert Opin. Drug Deliv., 2009, 6(4), 333-341.
[http://dx.doi.org/10.1517/17425240902828304] [PMID: 19348603]
[3]
Takashima, T.; Hashizume, Y.; Katayama, Y.; Murai, M.; Wada, Y.; Maeda, K.; Sugiyama, Y.; Watanabe, Y. The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [11C]telmisartan. Mol. Pharm., 2011, 8(5), 1789-1798.
[http://dx.doi.org/10.1021/mp200160t] [PMID: 21812443]
[4]
Celik, T.; Iyisoy, A.; Kursaklioglu, H.; Yilmaz, M.I.; Kose, S.; Kilic, S.; Amasyali, B.; Demirkol, S.; Isik, E. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin. Cardiol., 2005, 28(6), 298-302.
[http://dx.doi.org/10.1002/clc.4960280609] [PMID: 16028466]
[5]
Thomas, G.N.; Chan, P.; Tomlinson, B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging, 2006, 23(2), 131-155.
[http://dx.doi.org/10.2165/00002512-200623020-00004] [PMID: 16536636]
[6]
Amrinder, S.; Jha, K.K.; Anuj, M.; Amit, K. A Review on Telmisartan. J. Sci. Innov. Res., 2013, 2(1), 160-175.
[7]
Stangier, J.; Su, C.A.; Roth, W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res., 2000, 28(4), 149-167.
[http://dx.doi.org/10.1177/147323000002800401] [PMID: 11014323]
[8]
Zhang, Y.; Jiang, T.; Zhang, Q.; Wang, S. Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property. Eur. J. Pharm. Biopharm., 2010, 76(1), 17-23.
[http://dx.doi.org/10.1016/j.ejpb.2010.05.010] [PMID: 20685333]
[9]
Zhang, Y.; Zhi, Z.; Jiang, T.; Zhang, J.; Wang, Z.; Wang, S. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J. Control. Release, 2010, 145(3), 257-263.
[http://dx.doi.org/10.1016/j.jconrel.2010.04.029] [PMID: 20450945]
[10]
Sekar, V.; Chellan, V.R. Immediate release tablets of telmisartan using superdisintegrant-formulation, evaluation and stability studies. Chem. Pharm. Bull. (Tokyo), 2008, 56(4), 575-577.
[http://dx.doi.org/10.1248/cpb.56.575] [PMID: 18379110]
[11]
Koilkonda, P.; Lekkala, A.R.; Golla, C.M.K.; Ganji, S.R.; Konda, R.B. Amorphous Telmisartan US patent, 0111417 A1, 2006.
[12]
Patel, J.; Kevin, G.; Patel, A.; Raval, M.; Sheth, N. Design and development of a self-nanoemulsifying drug delivery system for telmisartan for oral drug delivery. Int. J. Pharm. Investig., 2011, 1(2), 112-118.
[http://dx.doi.org/10.4103/2230-973X.82431] [PMID: 23071930]
[13]
Zhong, L.; Zhu, X.; Yu, B.; Su, W. Influence of alkalizers on dissolution properties of telmisartan in solid dispersions prepared by cogrinding. Drug Dev. Ind. Pharm., 2014, 40(12), 1660-1669.
[http://dx.doi.org/10.3109/03639045.2013.841188] [PMID: 24099550]
[14]
Zhong, L.; Zhu, X.; Luo, X.; Su, W. Dissolution properties and physical characterization of telmisartan-chitosan solid dispersions prepared by mechanochemical activation. AAPS PharmSciTech, 2013, 14(2), 541-550.
[http://dx.doi.org/10.1208/s12249-013-9937-1] [PMID: 23430728]
[15]
Thipparaboina, R.; Kumar, D.; Chavan, R.B.; Shastri, N.R. Multidrug co-crystals: towards the development of effective therapeutic hybrids. Drug Discov. Today, 2016, 21(3), 481-490.
[http://dx.doi.org/10.1016/j.drudis.2016.02.001] [PMID: 26869329]
[16]
Arora, P.; Kaur, A.; Haneef, J.; Chadha, R. Solubility improvement of telmisartan by cocrystallization with citric acid. Int. J. Pharm. Sci. Res., 2017, 8, 3768-3775.
[17]
Renu, C.; Swati, B.; Jamshed, H.; Sadhika, K.; Sanjay, M. Cocrystals of telmisartan: characterization, structure elucidation, in-vivo, and toxicity studies. CrystEngComm, 2014, 16, 8375-8389.
[http://dx.doi.org/10.1039/C4CE00797B]
[18]
Haneef, J.; Chadha, R. Drug-drug multicomponent solid forms: cocrystal, coamorphous and eutectic of three poorly soluble antihypertensive drugs using mechanochemical approach. AAPS PharmSciTech, 2017, 18(6), 2279-2290.
[http://dx.doi.org/10.1208/s12249-016-0701-1] [PMID: 28101724]
[19]
Ganesh, M.; Ubaidulla, U.; Rathnam, G.; Jang, H.T. Chitosan-telmisartan polymeric cocrystals for improving oral absorption: In vitro and in vivo evaluation. Int. J. Biol. Macromol., 2019, 131, 879-885.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.03.141] [PMID: 30905757]
[20]
Alatas, F.; Ratih, H.; Soewandhi, S.N. Enhancement of solubility and dissolution rate of telmisartan by telmisartan-oxalic acid cocrystal formation. Int. J. Pharm. Pharm. Sci., 2015, 7, 423-426.
[21]
Wu, G. Amino acids: metabolism, functions, and nutrition. Amino Acids, 2009, 37(1), 1-17.
[http://dx.doi.org/10.1007/s00726-009-0269-0] [PMID: 19301095]
[22]
Tilborg, A.; Norberg, B.; Wouters, J. Pharmaceutical salts and cocrystals involving amino acids: a brief structural overview of the state-of-art. Eur. J. Med. Chem., 2014, 74, 411-426.
[http://dx.doi.org/10.1016/j.ejmech.2013.11.045] [PMID: 24487190]
[23]
Jensen, K.T.; Löbmann, K.; Rades, T.; Grohganz, H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline. Pharmaceutics, 2014, 6(3), 416-435.
[http://dx.doi.org/10.3390/pharmaceutics6030416] [PMID: 25025400]
[24]
Shaikh, N.S.; Bhalerao, A.V.; Adepwar, S.P.; Pentewar, R.S. Kazi; Talde, S.; Nishat. Solubility Enhancement technique for an anti-malarial drug using amino acid. Pelagia Res. Libr., 2015, 6, 27-40.
[25]
Alaayedi, M.I.; Mohammed, A.R.A. Pre-formulation and systematic evaluation of amino acid assisted permeability of insulin across in vitro buccal cell layers. Sci. Rep., 2016, 6, 32498.
[26]
Ojarinta, R.; Heikkinen, A.T.; Sievänen, E.; Laitinen, R. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin. Eur. J. Pharm. Biopharm., 2017, 112, 85-95.
[http://dx.doi.org/10.1016/j.ejpb.2016.11.023] [PMID: 27888143]
[27]
Elbagerma, M.A.; Edwards, H.G.M.; Munshi, T.; Hargreaves, M.D.; Matousek, P.; Scowen, I.J. Characterization of new cocrystals by raman spectroscopy, powder x-ray diffraction, differential scanning calorimetry, and transmission raman spectroscopy. Cryst. Growth Des., 2010, 10(5), 2360-2371.
[http://dx.doi.org/10.1021/cg100156a]
[28]
Indian Pharmacopoeia; The Indian pharmacopoeia commission, 2014.
[29]
Szepes, A.; Szabó-Révész, P.; Bajdik, J.; Kása, P., Jr; Neményi, M.; Pap, R.; Kovács, A.J.; Pintye-Hódi, K. Characterization and utilization of starches extracted from florencia and waxy maize hybrids for tablet formulation: compaction behaviour and tablet properties. Am. J. Plant Sci., 2014, 5(06), 69-72.
[http://dx.doi.org/10.4236/ajps.2014.56093]
[30]
Organization, W.H.S. 3.6. Bulk Density and Tapped Density of Powders; The International Pharmacopoeia, 2012, pp. 1-6.

Rights & Permissions Print Cite
Article Metrics
16
© 2024 Bentham Science Publishers | Privacy Policy